RxSight, Inc. RXST
Ophthalmic Goods · IPO 2021 · data as of November 13, 2026
RxSight, Inc. (RXST) is a healthcare company listed in the US with a market value of about $223M. In the twelve months to September 30, 2026 it had revenue of $122M and net income of -$53M, a net margin of -43.8%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).
Key numbers: a price to free cash flow of 12.0, 5-year revenue growth of 56% a year, a 5-year average ROIC of -21%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 79% below the current price.
About RxSight
RxSight is listed in the US and classified in ophthalmic goods, IPO year 2021. Revenue went from $15M in 2020 to $134M in 2025, growth of about 55.7% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 48% over three years (dilution for shareholders). It spends 29% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/FCF below 20
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $122M | $134M | $140M | $89M | $49M | $23M | $15M |
| Net income | -$53M | -$39M | -$27M | -$49M | -$67M | -$49M | $28M |
| Free cash flow | $19M | -$19M | -$22M | -$46M | -$61M | -$47M | -$38M |
| EPS (diluted) | $-1.28 | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 | $0.15 |
| Net margin | -43.8% | -29.0% | -19.6% | -54.6% | -136.2% | -215.5% | 187.9% |
| ROIC | — | -13.3% | -9.9% | -24.2% | -37.1% | -22.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $6.10, 15% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Hold”; expected EPS is $-0.13 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is RxSight stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 79% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does RxSight pay a dividend?
Not currently.
Is RxSight a good stock to buy?
We do not give buy or sell advice. RxSight scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.